Emergent BioSolutions (EBS) said Tuesday that it has obtained exclusive commercial rights in the US and Canada to Hikma Pharmaceuticals' Kloxxado Nasal Spray, an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose.
Financial terms were not disclosed.
Under the terms of the six-year agreement, Emergent said Hikma will continue to manufacture Kloxxado Nasal Spray 8 mg, which will become part of Emergent's NARCANDirect online distribution network for direct purchasers, such as emergency medical services.
Emergent's shares were up about 3% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。